Enoxaparin Sodium

依诺肝素钠

Report date: 2026/05/21 20:00:22

Base Information

Drug NameEnoxaparin Sodium
Drug Alias Name伊诺肝素钠Deciparenoxaparinum natricumenoxaparina de sodioKlexane +[15] 
ClassificationNatural product/Extract > Animal extract
Mechanisms of ActionAntithrombin-III activatorsFactor Xa inactivationThrombin inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hip FracturesHypoxia +[40] 
Global Approved IndicationsVenous ThrombosisST Elevation Myocardial InfarctionMyocardial Infarction +[4] 
Approved Indications in ChinaST Elevation Myocardial InfarctionMyocardial Infarction
Original Approved Country/TerritoryUnited States
Original Approved Date1993/03/29
Country/TerritoryBelgiumBulgariaCanada +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityValeo Pharma IncJohns Hopkins All Children'S Hospital Inc +[8] 
Inactive CompaniesDana-Farber Cancer InstituteAzidus BrasilUniversity of Texas Southwestern Medical Center +[22] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Postoperative ComplicationsIntraoperative Complications +[17] 
Inactive IndicationsHip FracturesHypoxiaObesity, Morbid +[23] 

Other Information

ATC CodeB01AB05
Related LinksWikipediaDrugBankKEGG